No licensed hantavirus vaccine exists as of May 2026, with all candidates remaining in preclinical or early-phase development stages that preclude U.S. or global approval this year. Moderna’s mRNA candidate with Korea University and several DNA-based approaches, including one showing neutralizing antibodies in a small Phase 1 trial, have yet to enter pivotal human efficacy studies, and standard regulatory timelines require multiple years beyond current readiness. Recent 2026 outbreaks have heightened surveillance and research interest, yet they have not accelerated funding or trial progression to close the gap. Trader consensus at 91.5% “No” reflects these verifiable pipeline constraints, though an unforeseen emergency-use authorization or accelerated review could theoretically alter the outlook if a late-stage candidate suddenly advances.